熊果酸靶向髓样分化蛋白-2的抗脓毒症机制研究
该研究以髓样分化蛋白-2(MD-2)为靶点,用生物膜干涉技术和分子对接检测熊果酸与MD-2的结合,并在Raw 264.7细胞中观察8、40、100 mg/L熊果酸对LPS(100 μg/L)刺激后炎症因子释放及LPS-TLR4/MD-2-NF-κB通路表达的影响。结果显示熊果酸与MD-2疏水腔结合,解离常数KD=1.43×10-4,8、40、100 mg/L熊果酸组细胞活力分别为96.01%、94.32%、92.12%,与空白组(100%)无显著差异。100 mg/L熊果酸组较LPS组显著降低IL-1β、IL-6、TNF-α、NO水平及TNF-α、IL-6、IL-1β、iNOS、COX-2 mRNA表达和MD-2、MyD88、p-NF-κB p65、iNOS蛋白表达(均P<0.01)。结论为熊果酸通过阻断MD-2调控LPS-TLR4/MD-2-NF-κB通路发挥抗脓毒症作用,属体外机制研究。
要点
- 熊果酸可与MD-2疏水腔结合,解离常数KD=1.43×10-4,为其靶向MD-2提供依据。
- 8、40、100 mg/L熊果酸组细胞活力分别为96.01%、94.32%、92.12%,与空白组(100%)无显著差异。
- 100 mg/L熊果酸组较LPS组显著降低IL-1β(38.018±0.675 vs. 111.324±1.262 μmol/L)、IL-6(35.052±1.664 vs. 115.255±5.392 μmol/L)、TNF-α(39.078±2.741 vs. 119.035±4.269 μmol/L)、NO(40.885±2.372 vs. 123.405±1.291 μmol/L),均P<
- 100 mg/L熊果酸组较LPS组显著下调TNF-α、IL-6、IL-1β、iNOS、COX-2 mRNA表达及MD-2、MyD88、p-NF-κB p65、iNOS蛋白表达(均P<0.01),NF-κB p65总蛋白三组间无差异。
- 上述结果为Raw 264.7细胞体外实验,尚未提供动物或临床数据。
适用人群与场景
- 体外实验:Raw 264.7细胞,使用第2代细胞,细胞密度达80%-90%时传代。
处置流程与药物剂量
- 细胞分组:空白组、LPS组(LPS 100 μg/L)、熊果酸组(先加8、40或100 mg/L熊果酸,再用100 μg/L LPS处理)。
研究设计与关键结果
- 研究类型:体外细胞机制研究;对象:Raw 264.7细胞;干预:熊果酸8、40、100 mg/L;对照:空白组与LPS 100 μg/L组。
- 生物膜干涉技术显示熊果酸与MD-2高亲和力结合,KD=1.43×10-4;分子对接显示熊果酸通过疏水键与MD-2氨基酸残基结合于疏水腔。
- MTT法显示8、40、100 mg/L熊果酸组细胞活力分别为96.01%、94.32%、92.12%,与空白组(100%)比较无显著差异。
- 与空白组比较,LPS组NO、TNF-α、IL-6、IL-1β水平显著升高;8、40、100 mg/L熊果酸处理可显著降低上述因子,且浓度越高效果越明显(100 mg/L组与LPS组比较均P<0.01,具体数值见key_points)。
- 与空白组比较,LPS组TNF-α、IL-6、IL-1β、iNOS、COX-2 mRNA表达显著升高,MD-2、MyD88、p-NF-κB p65、iNOS蛋白表达显著上调;100 mg/L熊果酸组较LPS组上述mRNA和蛋白表达均显著降低(均P<0.01),NF-κB p65总蛋白三组间无差异。
证据类型、等级与局限
- 证据类型:体外细胞实验(Raw 264.7细胞)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文为体外细胞机制研究,未提供动物或临床推荐;作者认为熊果酸通过阻断MD-2调控LPS-TLR4/MD-2-NF-κB通路发挥抗脓毒症作用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To explore the mechanism of ursolic acid in treating sepsis using myeloid differentiation protein-2 (MD-2) as the research carrier.
METHODS: The affinity of ursolic acid and MD-2 was determined by biofilm interferometry technique, and the bonding mode between ursolic acid and MD-2 was tested with the aid of molecular docking technique. Raw 264.7 cells were cultured in RPMI 1640 medium and subcultured was conducted when the cell density reached 80%-90%. The second-generation cells were used for in the experiment. The effects of 8, 40 and 100 mg/L ursolic acid on cell viability were assessed by methyl thiazolyl tetrazolium (MTT) method. Cells were divided into blank group, lipopolysaccharide (LPS) group (LPS 100 μg/L) and ursolic acid group (100 μg/L LPS treatment after addition of 8, 40 or 100 mg/L ursolic acid). The effect of ursolic acid on the release of cytokines nitric oxide (NO), tumor necrosis factor-α (TNF-α) and interleukins (IL-6, IL-1β) were evaluated by enzyme-linked immunosorbent assay (ELISA). The influence of ursolic acid on the mRNA expressions of TNF-α, IL-6, IL-1β, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) were detected by reverse transcription-polymerase chain reaction (RT-PCR). The implication of ursolic acid on the protein expressions of LPS-Toll-like receptor 4 (TLR4)/MD-2-nuclear factor-κB (NF-κB) pathway were tested by Western blotting.
RESULTS: Ursolic acid could bind to the hydrophobic cavity of MD-2 through hydrophobic bond with the amino acid residues of the protein. Therefore, ursolic acid showed high affinity with MD-2 [dissociation constant (KD) = 1.43×10-4]. The cell viability were decreased slightly, with the concentration of ursolic acid increasing, and the cell viability of 8, 40 and 100 mg/L ursolic acid were 96.01%, 94.32% and 92.12%, respectively, and there was no significant difference compared with the blank group (100%). Compared with the blank group, the cytokine level of the LPS group was significantly increased. The level of cytokines were significantly reduced by the treatment of 8, 40 and 100 mg/L ursolic acid, and the higher the concentration, the more obvious effect [compared between 100 mg/L ursolic acid group and LPS group: IL-1β (μmol/L): 38.018±0.675 vs. 111.324±1.262, IL-6 (μmol/L): 35.052±1.664 vs. 115.255±5.392, TNF-α (μmol/L): 39.078±2.741 vs. 119.035±4.269, NO (μmol/L): 40.885±2.372 vs. 123.405±1.291, all P < 0.01]. Compared with the blank group, the mRNA expressions of TNF-α, IL-6, IL-1β, iNOS and COX-2 in the LPS group were significantly increased, and the protein expressions of MD-2, myeloid differentiation factor 88 (MyD88), phosphorylation NF-κB p65 (p-NF-κB p65) and iNOS in the LPS-TLR4/MD-2-NF-κB pathway were significantly up-regulated. Compared with the LPS group, the mRNA expressions of TNF-α, IL-6, IL-1β, iNOS and COX-2 were significantly reduced by the treatment of 100 mg/L ursolic acid bound with MD-2 protein [TNF-α (2-ΔΔCt): 4.659±0.821 vs. 8.652±0.787, IL-6 (2-ΔΔCt): 4.296±0.802 vs. 11.132±1.615, IL-1β (2-ΔΔCt): 4.482±1.224 vs. 11.758±1.324, iNOS (2-ΔΔCt): 1.785±0.529 vs. 4.249±0.811, COX-2 (2-ΔΔCt): 5.591±1.586 vs. 16.953±1.651, all P < 0.01], and the proteins expressions of MD-2, MyD88, p-NF-κB p65 and iNOS in the LPS-TLR4/MD-2-NF-κB pathway were significantly down-regulated (MD-2/β-actin: 0.191±0.038 vs. 0.704±0.049, MyD88/β-actin: 0.470±0.042 vs. 0.875±0.058, p-NF-κB p65/β-actin: 0.178±0.012 vs. 0.571±0.012, iNOS/β-actin: 0.247±0.035 vs. 0.549±0.033, all P < 0.01). However, there was no difference in protein expression of NF-κB p65 among the three groups.
CONCLUSIONS: Ursolic acid inhibits the release and expression of cytokines and mediators and regulates LPS-TLR4/MD-2-NF-κB signaling pathway by blocking MD-2 protein, and thus plays an anti-sepsis role.
参考来源
- Chen G, Liu C, Zhang M, et al. [Study on the anti-sepsis mechanism of ursolic acid by targeting myeloid differentiation protein-2]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023. PMID: 37308226. doi:10.3760/cma.j.cn121430-20220705-00634
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。